Research background
Tirzepatide is a 39-residue synthetic peptide engineered from the GIP scaffold with sufficient GLP-1 receptor cross-reactivity to act as a dual incretin agonist. Its appearance in the literature reopened comparative questions about whether combined GIP and GLP-1 pathway engagement produces additive or distinct downstream signatures relative to single-receptor agonists.


